Celecoxib 化学構造
分子量: 381.37

高品質保証

カスタマーフィードバック(2)

Quality Control & MSDS

製品説明

  • Compare COX Inhibitors
    COX製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 セレコキシブは、40nMのIC50による選択的なCOX-2阻害剤です。
ターゲット COX-2
IC50 40 nM [1]
In vitro試験 Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A549 MnfVSpVv[3Srb36gRZN{[Xl? NHi3fFIxNjFvM{Cg{txO MXq0PEBp M1HLWolv\HWlZYOgTWNCVS1zIHX4dJJme3Orb36gc44h[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVt M{\KUlI3PTF|MUey
H460 NXfGfGVKTnWwY4Tpc44hSXO|YYm= M4\3SlAvOS1|MDFOwG0> MljyOFghcA>? M4rW[Ylv\HWlZYOgTWNCVS1zIHX4dJJme3Orb36gc44h[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVt M1jhfFI3PTF|MUey
HKESC-2 NX[3fJByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXXPZBtOjEEoN88US=> NXrrUGlLPDkEoHlCpC=> NHL4N|F{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW|IH;mJI95[WyrcHzheIlvyqB? MWiyOlQ4PDZ7Mx?=
CaES-17 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vPW|IxyqEQvF2= NGnreZA1QMLiaNMg NHr5SpR{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW|IH;mJI95[WyrcHzheIlvyqB? NVjXNnlDOjZ2N{S2PVM>
HKESC-2 M1jvVGFxd3C2b4Ppd{BCe3OjeR?= NU\KbFFTOjEEoN88US=> MYG0POKhcMLi M1XucZJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> MWqyOlQ4PDZ7Mx?=
CaES-17 M4PmcGFxd3C2b4Ppd{BCe3OjeR?= MV[yNOKh|ryP Moi5OFjDqGkEoB?= M1\Se5Jm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> NEDyd48zPjR5NE[5Ny=>
A549 NH7zfFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL3bpc2NTF4MDFOwG0> M2TFfVQ5yqCqwrC= NX[2WXdnTE2VTx?= NXPCSHZHUUN3ME2xOlMvPCEQvF2= M1nvRlI3PDZ2NkSz
HCC827 M{Psfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm0OU0yPjBizszN Mn\JOFjDqGkEoB?= M135e2ROW09? NWHKO3A6UUN3ME22PU4zKM7:TR?= MnTnNlY1PjR4NEO=
A549 M3TBZmFxd3C2b4Ppd{BCe3OjeR?= NV;ZWYRzQDBiwsXN M1HsO|Q5yqCqwrC= MUDEUXNQ MnvVbY5lfWOnczDhdI9xfG:|aYO= MX:yOlQ3PDZ2Mx?=
HCC827 MYHBdI9xfG:|aYOgRZN{[Xl? NFW4WZo5OCEEtV2= Mon0OFjDqGkEoB?= MoLtSG1UVw>? M1TkWYlv\HWlZYOgZZBweHSxc3nz NID3SIwzPjR4NE[0Ny=>
SGC-7901/DDP MVLGeY5kfGmxbjDBd5NigQ>? NYra[nRjOTEEoNM1US=> M2r3W|I1KGh? NXK1ZpFFcW6qaXLpeJMh[3mlbH;vfJlo\W6jc3WtNkBidmRiUD3ncJlkd3C{b4TlbY4h\XiycnXzd4lwdg>? M3;veFI3PDB5NkWz
SGC-7901  Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlryNlTDqGkEoB?= MknKTWM2OD1zMUWuNFgh|ryP NIDxNpczPjRyN{[1Ny=>
SGC-7901/DDP M3ThZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\INlTDqGkEoB?= NWTmZ|N3UUN3ME2zOU41PSEQvF2= NWHz[5BxOjZ2MEe2OVM>
SGC-7901/DDP MmTvRZBweHSxc3nzJGF{e2G7 Mli3NVDDqML3TR?= NFrPWFIzPCCq MnPzbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCC5aYToJINqe3CuYYTpci=> MYKyOlQxPzZ3Mx?=
SGC-7901/DDP NYPENlBUTnWwY4Tpc44hSXO|YYm= NIi0TlIyOMLiwsXN NGrrSG0zPCCq NW\1UphscW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YhWC2pbInjc5Bzd3SnaX6geIhzd3WpaDDicI9kc2mwZzDFVFItKGGwZDDpcoFkfGm4YYTpcochWEuDIHHu[EBEWkWEwrC= NWLlbYh[OjZ2MEe2OVM>
SGC-7901/DDP M3;jN2Z2dmO2aX;uJGF{e2G7 M1jpU|ExyqEEtV2= MluxNlQhcA>? NYDjZYVI[2G3c3XzJIEhdWG{a3XkJIRm[3KnYYPlJIlvKHSqZTDs[ZZmdCCxZjDCZ4wuOiCycn;0[Ylv NVTwfXZYOjZ2MEe2OVM>
H357 NGn3fnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjkNVE4NjVxMUCg{txO MVe0PEBp NVnLW3dFTE2VTx?= NEPnbItqdmirYnn0d{Bk\WyuIHfyc5d1cMLiY3;tZolv\WRid3n0bEBU[WK3dH;jcIF5 NX30b|lYOjZyMEm4O|Q>
TAF MlrXSpVv[3Srb36gRZN{[Xl? M3PaR|ExyqEEtV2= NYDMZpFuPyCm MnXXZYZn\WO2czDURWZ{KGGmaHXzbZZmKHC{b4DldpRq\XN? NU\yW5lqOjV7OEexNlc>
TAF M4i2cGZ2dmO2aX;uJGF{e2G7 NV;xTHptOTEEoNM1US=> MVizNE0yOjBibXnu NUjLXGFXeG:xcnz5JIFn\mWldIOg[GFsfCCyaH;zdIhwenmuYYTpc44h[2:wc3XxeYVvfCC2bzDFS2Yhe2mpbnHsbY5o MmXFNlU6QDdzMke=
TAF MnXsSpVv[3Srb36gRZN{[Xl? MWOxNOKhyrWP MYG0PEBp MW\pcoNz\WG|ZYOgSWdHWiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? M{PLb|I2QTh5MUK3
PANC-1 M33xVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDQNlAwPjBxMUCwJO69VQ>? NGPlPHYzPC92OD:3NkBp NEezfm9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NXK0eHh4OjV7N{OwOlI>
PANC-1 NWSweXZETnWwY4Tpc44hSXO|YYm= NIS1ZpAzOC94MD:xNFAh|ryP NF3yV|kzPCCq MmfBZZR1\W63YYTzJINmdGxiaX72ZZNqd25iYX7kJI1q\3KjdHnvckBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MWWyOVk4OzB4Mh?=
HeLa  NEf2NZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\j[4pFOjEEoN88UeKh MofkNlTDqGh? Mk\Q[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? MY[yOVc4ODR{Mx?=
SACC-83 NV\BZ3JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4npNVIxyqEQvF5CpC=> MVqyOOKhcA>? NIXj[nVmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?= NYjiZVlKOjV5N{C0NlM>
HeLa  NFzQT4hCeG:ydH;zbZMhSXO|YYm= NUD2Sol4OjEEoN88UeKh NIL2XW0zPMLiaB?= MkT5[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=> NIHNdVEzPTd5MESyNy=>
SACC-83 NE\oTW9CeG:ydH;zbZMhSXO|YYm= NGrvU4QzOMLizszNxsA> NHjaNZAzPMLiaB?= MlfF[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=> M3\HTlI2PzdyNEKz
HeLa  NInn[GtHfW6ldHnvckBCe3OjeR?= MoTGNlAwPDBxOECg{txO NIrTWmUzPMLiaB?= M1nhXZVxemWpdXzheJMhWFSHTjDwZZJ1cWGubImgZpkhcW6qaXLpeIlv\yCVcEGsJIFv\CCjY4TpeoF1\XNiUGTFUkBidmRiaX7hZ5RqfmG2ZYOgRWtV NGXndmEzPTd5MESyNy=>
SACC-83 MWHGeY5kfGmxbjDBd5NigQ>? MViyNE81OC96MDFOwG0> NUnpWXBFOjUEoHi= M4TLSpVxemWpdXzheJMhWFSHTjDwZZJ1cWGubImgZpkhcW6qaXLpeIlv\yCVcEGsJIFv\CCjY4TpeoF1\XNiUGTFUkBidmRiaX7hZ5RqfmG2ZYOgRWtV NFP0XW8zPTd5MESyNy=>
HLCZ01 NUX5NW1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOw5qCUPjEEoNM1US=> MVq0PEBp NIPuN4JFVVOR NWDuR4VucW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? Mm\pNlU4OjR6OUm=
HLCZ01 MXjGeY5kfGmxbjDBd5NigQ>? MWm0NOKh|ryP M3nIV|I1KGh? M{m4emROW09? MkPFbY5kemWjc3XzJIFk[3WvdXzheIlwdiCxZjDHNE9IOS2yaHHz[UBk\WyuczDjc41jcW6nZDD3bZRpKEmITj5OtS=> M1zhRlI2PzJ2OEm5
HLCZ01 MoDNRZBweHSxc3nzJGF{e2G7 M1ToelQxyqEQvF2= NUnZ[ohYOjRiaB?= NUfIeG06TE2VTx?= NYTQNIo4\W6qYX7j[ZMh[XCxcITvd4l{KGOxbXLpcoVlKHerdHigTWZPNc7z NX\GcXR3OjV5MkS4PVk>
HLCZ01 M{ju[mZ2dmO2aX;uJGF{e2G7 M1ToclQxyqEQvF2= M1S4XVI1KGh? NHS2WG5FVVOR MUjpcoNz\WG|ZYOgWHJCUUxiZYjwdoV{e2mxbjDjc41jcW6nZDD3bZRpKEmwdHXy[oVzd25vzsG= NX\nWZF5OjV5MkS4PVk>
MGC803 NUPCXZZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXuOHU1OC14MDFOwG0> MX23NkBp MVPJR|UxRTR5LkK15qCKyrIkgJm2MlQ{KM7:TR?= NXfsOIc{OjV5MEGzO|g>
SGC7901 MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPDTYVuOC14MDFOwG0> NGjiPZU4OiCq NUn3XVhVUUN3ME20N{42O+LCidMx5qCKPS5zMjFOwG0> MlvRNlU4ODF|N{i=
MGC803 MULGeY5kfGmxbjDBd5NigQ>? M4\5[VQxyqEQvF2= M3PKe|gwOTZxMkSgbC=> NVW4TZhxfXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v MlW2NlU4ODF|N{i=
SGC7901 MnTPSpVv[3Srb36gRZN{[Xl? MoL1OFDDqM7:TR?= NG\ESFk5NzF4L{K0JIg> M1XZcpVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> MX6yOVcxOTN5OB?=
MCF-7  NYPUd3JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoToNU8yOCEQvF2= M4jGUVczKGh? M4\k[WROW09? NXHrTHBu\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36= NVSxOIUzOjV4Nke1NVA>
MDA-MB-231  MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXflNmg2OS9zMDFOwG0> NV64R29jPzJiaB?= NF76NoNFVVOR MWTlcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>? M1u2XVI2PjZ5NUGw
MDA-MB-231 NHSxfZhHfW6ldHnvckBCe3OjeR?= MlPyNE01OCEEtV2= M1naOlQuOjRiaB?= M{jU[4lv[3KnYYPld{BEV1hvMjDwdo91\WmwIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> Mn\3NlU2QDd|Mkm=
MCF-7 M3zIPWZ2dmO2aX;uJGF{e2G7 NYPaSGlROC12MDFCuW0> M{PkNVQuOjRiaB?= NHXhRYJmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS|Ih\XiycnXzd4lwdsLi NX;CTndIOjV3OEezNlk>
MCF7-MX  MYHGeY5kfGmxbjDBd5NigQ>? NEnFVZgxNTRyINM1US=> MmfWOE0zPCCq M13Ie4VvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB? MYWyOVU5PzN{OR?=
MDA-MB-231 M1jHd2Z2dmO2aX;uJGF{e2G7 M3\U[VAuPDBiwsXN NVfScGk6PC1{NDDo MkHvd5RqdXWuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBCSkOJMjD1dEB1dyB2LkK3JJRqdWW|IITvJINwdnS{b3ygcIV3\WxiYomgNVIhcMLi MYCyOVU5PzN{OR?=
A2780 NV6wTodSTnWwY4Tpc44hSXO|YYm= NY\oZWs3PS9zMD:xOUDPxE1? M4TK[lQ5KGh? MXzk[YNz\WG|ZYOgR495NTJiZYjwdoV{e2mxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXSyOVQzPDh7OB?=
SKOV3  NHLGPJVHfW6ldHnvckBCe3OjeR?= MWG1M|ExNzF3IN88US=> NYjydlFuPDhiaB?= MnPa[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NF[zRm0zPTR{NEi5PC=>
A2780 Mn3XSpVv[3Srb36gRZN{[Xl? MnL1OU8yOC9zNTFOwG0> M1Pvd|Q5KGh? NIC3eW9mdGW4YYTld{B1cGViZYjwdoV{e2mxbjDv[kBGNWOjZHjldolvKGGwZDDr[ZJifGmw NV;sXIpbOjV2MkS4PVg>
SKOV3  MVnGeY5kfGmxbjDBd5NigQ>? NYf1flJSPS9zMD:xOUDPxE1? M1m0fVQ5KGh? NY[wVlVT\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= MVKyOVQzPDh7OB?=
A2780 Mn;wSpVv[3Srb36gRZN{[Xl? NIPkcGY2NzFyL{G1JO69VQ>? NEP6UWw1QCCq MYrk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5? NYS0eVhrOjV2MkS4PVg>
SKOV3  NWjXWIg1TnWwY4Tpc44hSXO|YYm= NVjFZ4hLPS9zMD:xOUDPxE1? NFX4OWg1QCCq MUDk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5? MXGyOVQzPDh7OB?=
A2780 NFn1RZhHfW6ldHnvckBCe3OjeR?= MYm1M|ExNzF3IN88US=> NIHMWoYyKGh? MoPXbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NV\YRYk2OjV2MkS4PVg>
SKOV3  NY\icVJrTnWwY4Tpc44hSXO|YYm= MkfhOU8yOC9zNTFOwG0> NXTXT4tQOSCq NFrsbmdqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NGrIRnEzPTR{NEi5PC=>
HCT-15 MmnvSpVv[3Srb36gRZN{[Xl? M2XhclExNTVyIN88US=> MnLSOk0{PiCq NHPPW4tqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy M1XaTFI2OjF6MEK4
HT-29  M372dGZ2dmO2aX;uJGF{e2G7 M1TNOVExNTVyIN88US=> MnrNOk0{PiCq Ml;obY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= Ml\TNlUzOThyMki=
HSC3  MmGwR4VtdCCYaXHibYxqfHliQYPzZZk> NEfLdnEx6oDVNECg{txO NIW5[Io1QCCq M1XCc2lEPTB;MkWuOeKyOS55OECg{txO MkjvNlUyQTh5OEm=
HSC3  NVfNeYpnSXCxcITvd4l{KEG|c3H5 NF3GZ24zPSEQvF2= MnvFOFghcA>? NUPzc2JlcW6mdXPld{BieG:ydH;zbZM> M{jrO|I2OTl6N{i5
HSC3  MmHlSpVv[3Srb36gRZN{[Xl? M3\GO|I2KM7:TR?= NUTXWZlmPDhiaB?= NHzYNZdmgGirYnn0d{B{cWewaX\pZ4FvfGy7IILl[JVk\WRibXnndoF1cW:wIHPvcYJqdmWmIIfpeIghS0WW NX2y[3g6OjVzOUi3PFk>
HSC3  NEnlc4dHfW6ldHnvckBCe3OjeR?= M{XIcVI2KM7:TR?= MYK0PEBp M{PMbYlvcGmkaYTzJGhUSzNiY3XscEBqdn[jc3nvckBkd22kaX7l[EB4cXSqIFPFWC=> NFLqWoszPTF7OEe4PS=>
HSC3  M2P1bWZ2dmO2aX;uJGF{e2G7 MXmyOUDPxE1? NX\DOlBoPzJiaB?= NXXaU|R6\GWlcnXhd4V{KE2PUD2yJIFv\CCPTWCtPUBxem:2ZXnud:Kh Mkm2NlUyQTh5OEm=
201T  M1TqcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:x[oFmPzJiaB?= MWHEUXNQ NHrC[5RKSzVyPUS4MlYhyrWP NV[zZVlyOjVyNUe5OFE>
273T MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXnZlFZPzJiaB?= MXfEUXNQ NEXIXGtKSzVyPUiwMlUhyrWP M{SzVlI2ODV5OUSx
Hep-2 NX3EfHRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K0[lMxNzVyL{GwNEDPxE1? MkXVNVIwOjRxM{[vOFghcA>? MX;EUXNQ MofobY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NUnFdlNEOjR7OUi1OlQ>
Hep-2 MX7BdI9xfG:|aYOgRZN{[Xl? NUHPVVhYPTBizszN MWCwMVQ5KGh? M3HvW2ROW09? MX7pcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWg[IVx\W6mZX70JI1idm6nch?= M3T5TVI1QTl6NU[0
Hep-2 NIPPV|ZHfW6ldHnvckBCe3OjeR?= NETYcoM2OCEQvF2= NXX1elQ5OC12ODDo NUe2e45qTE2VTx?= M1ywUZJm\HWlZYOgeIhmKHSnbH;t[ZJie2ViYXP0bZZqfHliZ4Lh[JVidGy7 NELNXI0zPDl7OEW2OC=>
Hep-2 MojhSpVv[3Srb36gRZN{[Xl? M2DqWFUxKM7:TR?= MY[wMVQ5KGh? MUfEUXNQ NH3DdIpl\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDoWGVTXA>? NH\ndG4zPDl7OEW2OC=>
SGC-7901 NGfZS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm4WmJFOTBxNUCvNVAxKM7:TR?= M{PrTlI1NzR6L{eyJIg> NXi3OHhqTE2VTx?= NGXo[HRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NXTQe|l2OjR7OUK5OVg>
MKN-45 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFuzdGMyOC93MD:xNFAh|ryP NUnke4ltOjRxNEivO|IhcA>? NX;G[VlYTE2VTx?= MlnybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M1X1fFI1QTl{OUW4
SGC-7901 MoXiSpVv[3Srb36gRZN{[Xl? MYixNE82OC9zMECg{txO MnH1OFghcA>? MXXEUXNQ NIf6OW9ld3ewcnXneYxifGW|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M{npOVI1QTl{OUW4
MKN-45 NUDoSWVnTnWwY4Tpc44hSXO|YYm= M2LOelExNzVyL{GwNEDPxE1? NITjbZI1QCCq NEX0SJhFVVOR NGH5Zodld3ewcnXneYxifGW|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M{WwOVI1QTl{OUW4
C666-1 NGPKN5pEgXSxdH;4bYNqfHliQYPzZZk> MYGyNE05OCEQvF2= NWTSbVdoOjRiaB?= NX;SOHl3\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? MlHwNlQ5PTR6M{i=
CNE-1 NHvYN|dEgXSxdH;4bYNqfHliQYPzZZk> NW\JPFA6OjBvOECg{txO MUSyOEBp NHqzSZVl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh M3TL[VI1QDV2OEO4
CNE-2 MWrDfZRwfG:6aXPpeJkhSXO|YYm= NF3IfYczOC16MDFOwG0> MWOyOEBp M2Kwc4Rm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> NWTQOJZsOjR6NUS4N|g>
C666-1 M1XMPGN6fG:2b4jpZ4l1gSCDc4PhfS=> M{nHN|YxKM7:TR?= MnLpO{Bl NY\EcFlv\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> MljJNlQ5PTR6M{i=
CNE-1 MoXkR5l1d3SxeHnjbZR6KEG|c3H5 MkHLOlAh|ryP NGXyWHk4KGR? Mkfx[Y5p[W6lZYOgdoFlcWG2aX;uJIN6fG:2b4jpZ4l1gSC2aILveYdpKEORWD2yMYRmeGWwZHXueEBu[W6wZYK= NVLnOXpsOjR6NUS4N|g>
SNU-1041 NXXVZWMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDCNE01OCEQvF2= MXG0PEBp M4e1[olvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NYTCTIZROjR4OUK3NFM>
SNU-1041 M1WyemZ2dmO2aX;uJGF{e2G7 Ml2xNlAwOzBizszN NGLySHk1KGh? MY\pcoR2[2W|IHX4dJJme3Orb36gc4bDqEOKT2CsJGdTWDd6wrDhcoTDqFiEUEJCpIF1KHSqZTDSUmEhdGW4ZX|CpC=> MVSyOFY6OjdyMx?=
SNU-1041 NG\jWlVHfW6ldHnvckBCe3OjeR?= M2LHWFAuPDBizszN MX20JIg> MWn1dE1z\We3bHH0[ZMhS0iRUNMgZYZ1\XJidILlZZRu\W62IIfpeIghcGmpaDDjc45k\W62cnH0bY9vew>? NH\wSWszPDZ7MkewNy=>
SGC-7901 NIXoOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX20dXhFPTBvMUK1JO69VQ>? NELLfHMzPC92OD:3NkBp NFnaS29qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NE\OPVUzPDZ5NkO5OC=>
SGC-7901 MlvKRZBweHSxc3nzJGF{e2G7 Ml65NVAxKM7:TR?= MnHhO|IhcA>? NWmzN5R6cW6mdXPld{BieG:ydH;zbZM> NFjxRVQzPDZ5NkO5OC=>
SGC-7901 M4HkOmZ2dmO2aX;uJGF{e2G7 NUfSc4YyPzVxMUCwM|EzPSEQvF2= MmjGNlQwPDhxN{KgbC=> NHPvWZRqdmO{ZXHz[ZMh[2G|cHHz[U05KGGwZDCtPUBuWk6DIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKG2jbn7ldi=> MkT3NlQ3PzZ|OUS=
LMeC  MnTmSpVv[3Srb36gRZN{[Xl? M4fFPVIxNzVyIN88US=> NHzDOok1QCCq NIK1Z4Zl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhS0:[LUKgdJJwfGWrbh?= MkTjNlQ3PTZ5NE[=
CMeC-1 M4HpSWNmdGxiVnnhZoltcXS7IFHzd4F6 M2DWR|IxNzVyIN88US=> MlLxOFghcA>? NYjCVlVCcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MUKyOFY2Pjd2Nh?=
LMeC MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1H3ZlIxNzVyIN88US=> MlnPOFghcA>? NFXINnJqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NFv0cVczPDZ3Nke0Oi=>
CMeC-1 NFO5ZpRHfW6ldHnvckBCe3OjeR?= Mlv4NlAwPTBizszN NH3XPY81QCCq NUTTc2hscW6mdXPld{BIOS2VIHHydoV{fA>? NEW4fYIzPDZ3Nke0Oi=>
LMeC MlriSpVv[3Srb36gRZN{[Xl? MmLGNlAwPTBizszN M1jlfFQ5KGh? M1z4NYlv\HWlZYOgS|EuWyCjcoLld5Q> MVSyOFY2Pjd2Nh?=
CMeC-1 M2PhPWZ2dmO2aX;uJGF{e2G7 M4m3flIxNzVyIN88US=> MUK0PEBp NXLDV2Nn\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MoT4NlQ3PTZ5NE[=
LMeC MojuSpVv[3Srb36gRZN{[Xl? M4jNNlIxNzVyIN88US=> MWG0PEBp M2jZS4Rm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUf5NnVHOjR4NU[3OFY>
CMeC-1 NGjNXolHfW6ldHnvckBCe3OjeR?= M{fx[VIxNzVyIN88US=> MVK0PEBp M1SxOIlv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> NGD4do4zPDZ3Nke0Oi=>
LMeC NUDwSXlnTnWwY4Tpc44hSXO|YYm= MmPpNlAwPTBizszN MVW0PEBp NYf3U3locW6mdXPld{Bk[XOyYYPlMVMh[WO2aY\heIlwdg>? M3nzXlI1PjV4N{S2
OVCAR-3 NXnOPYM4S2WubDDWbYFjcWyrdImgRZN{[Xl? Ml23NVAhyrWP Mlr6NUBp NXeyVI57\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? NX:wV4RHOjR3MkCyNlc>
OVCAR-3 NIjyZotCeG:ydH;zbZMhSXO|YYm= MUSxNEDDvU1? NWfibIR{OSCq NHPjTYZxem:vb4Tld{Bx[WOuaYThfIVtNWmwZIXj[YQh[XCxcITvd4l{yqB? NEXEWo8zPDV{MEKyOy=>
OVCAR-3 MUjGeY5kfGmxbjDBd5NigQ>? MWSxNEDDvU1? MV6xJIg> M1TQTIVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2VvOdMg NGHxV|gzPDV{MEKyOy=>
OVCAR-3 NULmSJlzTnWwY4Tpc44hSXO|YYm= NWPrN3lbOTBiwsXN M2P0XlEhcA>? MlHv[I94di2{ZXf1cIF1\XNiTl[t{tpDKGGldHn2ZZRqd25iaX7keYNm\CCkeTDwZYNtcXSjeHXs MVqyOFUzODJ{Nx?=
OVCAR-3 NGW0SHVHfW6ldHnvckBCe3OjeR?= MlrNNVAhyrWP MnvvNUBp NVqwWVZocW6qaXLpeJMheGGlbHn0ZZhmdC2rbnT1Z4VlKEGtdDDwbI9{eGixconsZZRqd25? MUSyOFUzODJ{Nx?=
CF33 M1nYRWZ2dmO2aX;uJGF{e2G7 NHnlVZAyODBizszN M{SxOVI1KGh? M2HT[4lv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gR29ZNTJicILveIVqdiCneIDy[ZN{cW:w NEfi[WIzPDVyM{e4Ni=>
CF33 MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjFS5AyOTBvMUCwJO69VQ>? M4jJUlAuPCCm MX3pcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MWiyOFUxOzd6Mh?=
CF33 MnTUSpVv[3Srb36gRZN{[Xl? MVuxNE0yODBizszN MoLiOE0zPCCq NFi3dGJl\WO{ZXHz[ZMh[2WubIOgbY4hfGinIGOgdIhie2ViYX7kJIlv[3KnYYPld{Bk\WyuczDpckBIOC:JMTDhdpJme3R? MWWyOFUxOzd6Mh?=
LNCaP NFnYfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TnSFIwPS9zMDFOwG0> NHO5RZg6PiCq MUjpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XSxco\hd5RifGmw MorrNlQzQTZ7N{i=
LNCaP NX;qOWRPSXCxcITvd4l{KEG|c3H5 Ml3VNk82NzFyIN88US=> NFfKWpA6PiCq NI\lSGZqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> NGDofGUzPDJ7Nkm3PC=>
PC-3  NVLTeo1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1eye|AuPTBizszN MUi0PQKBkWh? MYrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NHrVXJUzPDF{N{i4Ni=>
PC-3  NHjw[JFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnTqNE0yODBizszN Mom0O|IhcA>? NE\ISotl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NF3Db2gzPDF{N{i4Ni=>

... Click to View More Cell Line Experimental Data

In vivo試験 Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]
臨床試験 Celecoxib is currently in Phase II clinical trials in patients with recurrent respiratory papillomatosis.
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

COX enzyme assay in vitro Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.

細胞アッセイ: [2]

細胞株 HNE1 and CNE1-LMP1
濃度 0-75 μM
反応時間 48 hours
実験の流れ The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.

動物実験: [1]

動物モデル A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
製剤 Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
投薬量 ≤200 mg/kg
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Celecoxib SDF
分子量 381.37
化学式

C17H14F3N3O2S

CAS No. 169590-42-5
保管 2年-20℃
6月-80℃in solvent
別名 SC 58635
溶解度 (25°C) * In vitro DMSO 76 mg/mL (199.28 mM)
エタノール 33 mg/mL (86.53 mM)
<1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

カスタマーフィードバック (2)


Click to enlarge
Rating
Source Br J Pharmacol, 2014, 171(2), 498-508. Celecoxib purchased from Selleck
Method Metabolic evaluation
Cell Lines Wild-type and EC-AMPK mice
Concentrations 50 mg·kg−1 ·day−1
Incubation Time 4 weeks
Results The treatment with either drughad no effects on body weight and blood glucose levels(A), but significantly decreased the circulating triglyceride and cholesterol levels in EC-AMPK mice (B).

Click to enlarge
Rating
Source J Cell Physiol, 2014, 10.1002/jcp.24843. Celecoxib purchased from Selleck
Method Live-dead assay
Cell Lines HCC38 cells
Concentrations 5.0 uM
Incubation Time 24 h
Results Initial studies examined whether there was a toxic interaction between the PDE5 inhibitor sildenafil and the non-steroidal anti-inflammatory drug celecoxib. In mammary carcinoma cell lines growing in 10% fetal calf serum sildenafil and celecoxib interacted in a greater than additive fashion to kill parental wild type tumor cells as well as anoikis resistant variants of these cells.

文献中の引用 (6)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related COX 阻害剤

  • Xanthohumol

    Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Phase 1.

  • AZD3839

    AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.

  • A-438079 HCl

    A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.

  • PF-03084014 (PF-3084014)

    PF-03084014 (PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Phase 2.

  • Indomethacin

    Indomethacin(Indocid, Indocin) is a non-steroidal anti-inflammatory compound commonly used to reduce fever, pain, stiffness, and swelling.

  • Lornoxicam

    Lornoxicam is a COX-1 and COX-2 inhibitor with IC50 of 5 nM and 8 nM, respectively.

  • Aspirin

    Aspirin is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication.

  • Rofecoxib

    Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM.

  • Ketorolac

    Ketorolacは非選択COX阻害剤、人間COX-1とCOX-2に作用する時、IC50がそれぞれ1.23 µM と3.50 µM になる。

    Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).

最近チェックしたアイテム

Tags: Celecoxibを買う | Celecoxib供給者 | Celecoxibを購入する | Celecoxib費用 | Celecoxib生産者 | オーダーCelecoxib | Celecoxib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ